Coverage dated November 15, 2021 to November 16, 2021
Pfizer asks US officials to approve COVID-19 pill
Headline from Thv11
The company’s antiviral is one of a handful of pills that have recently been shown to significantly cut hospitalizations and deaths from COVID-19 infections.
Thv11's own description from its feed. We collect headlines and these descriptions, not full articles; read the original reporting below.
Pfizer is submitting its experimental pill for COVID-19 for U.S. authorization, setting the stage for a likely launch of the promising therapy in coming weeks.
WASHINGTON — Pfizer said Tuesday it is asking U.S. regulators to authorize its experimental pill for covid-19, setting the stage for a likely launch of the promising therapy in the coming weeks.
Pfizer plans to submit its application to the Food and Drug Administration on Tuesday seeking emergency authorization of its Covid-19 treatment pill, CEO Albert Bourla said. “We will submit as quickly as today,” Bourla said during a conference hosted by STAT news on Tuesday.
The company’s antiviral is one of a handful of pills that have recently been shown to significantly cut hospitalizations and deaths from COVID-19 infections.
WASHINGTON (AP) — Pfizer asked U.S. regulators Tuesday to authorize its experimental pill for COVID-19, setting the stage for a likely launch this winter of a promising treatment that can
The deal allows generic drug companies to make the COVID-19 pill for use in 95 countries, making it available to around 53 percent of the world's population.
Move could make treatment available to more than half the world’s population, by allowing generic drug companies to produce the pill cheaply in 95 low- and middle-income nations
The company conducted trials with unvaccinated people who were high-risk, due to age or health issues, who were showing early symptoms of COVID-19 infection.
COVID-19 news today: Pfizer's decision on antiviral pill could make treatment available to half world's population; Florida woman dies after suing over ivermectin.
US pharmaceutical giant Pfizer on Tuesday announced a deal to make its oral antiviral Covid-19 medication available more cheaply in poorer countries, if the promising pill passes trials and regulator…
Pfizer announced on Tuesday that it is allowing its antiviral COVID-19 pill to be made in poorer nations throughout the world in an effort to help arm them with tools to combat the pandemic.
LONDON — Drugmaker Pfizer Inc. has signed a deal with a U.N.-backed group to allow other manufacturers to make its experimental covid-19 pill, a move that could make the treatment available to more than half of the world’s population. In a statement issued Tuesday, Pfizer said it would grant a
The pill, which dramatically reduced the rate of death and hospitalization in people at high risk of severe illness from covid-19, is the second antiviral drug under Food and Drug Administration review.
The agreement allows generic manufacturers to make the pill widely available in 95 low- and middle-income countries covering 53% of the world's population.
This image provided by Pfizer shows its COVID-19 pill. Drugmaker Pfizer said Tuesday, Nov. 16, 2021, it is submitting its experimental pill for U.S. authorization, setting the stage for a
Drugmaker Pfizer Inc. has signed a deal with a U.N.-backed group to allow other manufacturers to make its experimental Covid-19 pill, a move that could make the treatment available to more than half of the world’s population.
US pharmaceutical company Pfizer on Tuesday asked regulators to authorize its Covid pill after it was shown to cut hospitalization or death by nearly 90 percent among newly-infected high risk patient…
COVID-19 patients in 95 developing countries — more than half the world's population — could soon receive lower-cost doses of Pfizer's new drug to treat the disease.
